Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia.

Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia.

<h4>Background</h4>To determine the immunogenicity, efficacy, reactogenicity, and safety of a single dose of recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV, 5 × 1010 viral particles per 0.5 mL dose), we conducted a single-dose, randomised, double-blind, placebo-control...

Full description

Bibliographic Details
Main Authors: Dmitry Lioznov, Irina Amosova, Savely A Sheetikov, Ksenia V Zornikova, Yana Serdyuk, Grigory A Efimov, Mikhail Tsyferov, Mikhail Khmelevskii, Andrei Afanasiev, Nadezhda Khomyakova, Dmitry Zubkov, Anton Tikhonov, Tao Zhu, Luis Barreto, Vitalina Dzutseva
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0278878

Internet

https://doi.org/10.1371/journal.pone.0278878

Similar Items